Drug Trial Radar · NCT07341373
A Single Bolus, 12-hour Euglycemic Clamp Study of the Safety, Pharmacokinetics (PK) and Glucodynamics (GD) of Intraperitoneal (IP) Portal Insulin U-500
Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
29
Actual
Start
Feb 10, 2026
Primary completion
Sep 30, 2026
Study completion Sep 30, 2026
Sponsor
- Lead sponsor
- Portal Diabetes, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 14, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to assess the safety of a new U500 insulin formulation and to determine how rapidly it is absorbed and how long it takes to act when administered intraperitoneally. The trial will be conducted in people with Type 1 Diabetes. The main questions it aims to answer are: Is the drug safe and tolerable when administered intraperitoneally? How fast is it absorbed, and how long does it take to act? Researchers will compare the investigational product (PI-U500) with Humulin R U500 administered intraperitoneally and Lyumjev U100 administered subcutaneously. Participants will undergo a 12-hour clamp procedure in which their blood glucose will be maintained stable via glucose infusion at variable rates after a single intraperitoneal injection of the insulin formulation.
Conditions
- Type 1 Diabetes
Interventions
Portal Insulin U-500Drug
Intraperitoneal delivery of a single dose at 0.1 U/kg during an euglycemic clamp
Portal Insulin U-500Drug
Intraperitoneal delivery of a single dose at 0.2 U/kg during an euglycemic clamp
Portal Insulin U-500Drug
Intraperitoneal delivery of a single dose at 0.3 U/kg during an euglycemic clamp
Humulin R U-500Drug
Intraperitoneal delivery of a single dose at 0.2 U/kg during an euglycemic clamp
Lyumjev U-100 InsulinDrug
Subcutaneous delivery of a single dose at 0.2 U/kg during an euglycemic clamp
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety: Incidence of adverse eventsTime frame: From enrollment until the follow-up visit, an average of 2 months
- Safety: Change from baseline in systolic and diastolic blood pressureTime frame: Will be measured at 2 times, first within 4 hours before drug administration (Pre-clamp) and then after 12 hours of drug administration (post-clamp)
- Safety: Change from baseline in temperatureTime frame: Will be measured at 2 times, first within 4 hours before drug administration (Pre-clamp) and then after 12 hours of drug administration (post-clamp)
- Safety: Change from baseline in respiratory rateTime frame: Will be measured at 2 times, first within 4 hours before drug administration (Pre-clamp) and then after 12 hours of drug administration (post-clamp)
- Safety: Change from baseline in heart rateTime frame: Will be measured at 2 times, first within 4 hours before drug administration (Pre-clamp) and then after 12 hours of drug administration (post-clamp)
- Safety: Change from baseline in 12-lead electrocardiogram (ECG) parametersTime frame: Pre-dose and after the end of PK-sampling (720 minutes post-dose)
- Safety: Incidence and severity of clinical findings on physical examinationTime frame: Pre-dose and after the end of PK-sampling (720 minutes post-dose)
- Tolerability: Pain assessments per Visual Analogue Scale (VAS)Time frame: 10 min and 1 hour post-dosing
- Tolerability: Change in Interleukin 6 [IL-6] levelsTime frame: Blood samples will be taken immediately before dosing, 2 hours after dosing, and with the last PK sample (720 minutes after dosing)
- Tolerability: Change in tumor necrosis factor [TNF-α] levelsTime frame: Blood samples will be taken immediately before dosing, 2 hours after dosing, and with the last PK sample (720 minutes after dosing)
- Tolerability: Change in high sensitivity C-reactive protein [hsCRP] levelsTime frame: Blood samples will be taken immediately before dosing, 2 hours after dosing, and with the last PK sample (720 minutes after dosing)
- Pharmacokinetic: Area under the insulin concentration-time curve (AUC)Time frame: From the time of dose (time 0) until 12 hours post-dose (AUCIns,0-12h)
- Pharmacokinetic: Maximum insulin concentration (Cmax)Time frame: Over 12 hours post-dosing
- Pharmacokinetic: Time to maximum insulin concentration (Tmax)Time frame: Over 12 hours post-dosing
- Glucodynamic: Area under the glucose infusion rate (GIR) time curveTime frame: From the time of dose (time 0) until 12 hours post-dose (AUCGIR,0-12h)
- Glucodynamic: Maximum GIR (GIRmax)Time frame: Over 12 hours post-dosing
- Glucodynamic: Time to maximum GIR (TGIRmax)Time frame: Over 12 hours post-dosing
Locations
1 site in 1 country. Site status is shown where the registry gives one.
ProSciento, Inc.
Chula Vista, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.